SoftBank (SB Investment Advisers) 13F: Q2 2026 Portfolio — $7.66B Across 9 Positions

SoftBank (SB Investment Advisers) · Masayoshi Son · Q2 2026

Portfolio stays fully concentrated, with trimming focused on Compass and Aurora Innovation

Reported value

$7.66B

Filed 2026-08-14

Positions

Quarter ended 2026-06-30

Top 10 weight

100.0%

New0Added0Trimmed2Exited1View the SEC filing

Form 13F reports long US-listed positions only, up to 45 days after quarter end. It excludes shorts, cash, and non-US holdings, so the live book can differ.

SoftBank (SB Investment Advisers) reported a $7.66B US-listed portfolio in its Q2 2026 Form 13F, filed with the SEC on 2026-08-14 for the quarter ended 2026-06-30. The book holds 9 positions, led by Coupang at 65.6% of reported value; the top three together account for 92%. Against the Q1 2026 filing, the manager opened 0 new positions, added to 0, trimmed 2, and exited 1.

Top 9 holdings

Portfolio allocation

CoupangCPNG65.6%
Grab Holdings LimitedGRAB19.8%
Relay TherapeuticsRLAY6.8%
CompassCOMP3.5%
Vir BiotechnologyVIR1.5%
Aurora InnovationAUR1.3%
Energy Vault HoldingsNRGV0.9%
Full Truck AllianceYMM0.6%
Ginkgo Bioworks HoldingsDNA0.1%

Share of reported 13F value

#	Holding	Action	Weight	Value	Shares vs prior quarter
1	CoupangCPNG	Unchanged	65.6%	$5.03B	0.0%
2	Grab Holdings LimitedGRAB	Unchanged	19.8%	$1.51B	0.0%
3	Relay TherapeuticsRLAY	Unchanged	6.8%	$522M	0.0%
4	CompassCOMP	Trimmed	3.5%	$265M	-2.3%
5	Vir BiotechnologyVIR	Unchanged	1.5%	$112M	0.0%
6	Aurora InnovationAUR	Trimmed	1.3%	$97.4M	-27.9%
7	Energy Vault HoldingsNRGV	Unchanged	0.9%	$73.2M	0.0%
8	Full Truck AllianceYMM	Unchanged	0.6%	$42.8M	0.0%
9	Ginkgo Bioworks HoldingsDNA	Unchanged	0.1%	$6.05M	0.0%

Values and share counts as reported for 2026-06-30; weights are share of reported 13F value.

Actions compare share counts against the prior quarter's filing, so they do not move with price.

New positions and exits

New positions

No new positions this quarter.

Closed out

Roivant Sciences$74.0M

Read on the quarter

What the moves add up to

In Q2 2026, SoftBank (SB Investment Advisers) maintained an extremely concentrated 9-position portfolio, with the top 10 accounting for 100.0% of total value. The centre of gravity remained in Coupang at 65.64% weight and Grab Holdings Limited at 19.77%, while the remaining holdings were comparatively small—ranging down to 0.08% in Ginkgo Bioworks Holdings.

Activity was light: there were no new positions or adds, versus 2 trims and 1 exit. The trims were targeted—shares in Compass fell, with share count down 2.3%, and Aurora Innovation was reduced more sharply, with share count down 27.9%. Separately, Roivant Sciences was exited entirely, marking a clean reduction in exposure, even as the two largest positions were held steady (no share-count change) in both Coupang and Grab.

Context

How to read this filing

A Form 13F is a quarterly snapshot institutional managers with over $100M in US-listed assets must file within 45 days of quarter end. It shows long equity positions only: no short book, no cash, no non-US listings, no timing inside the quarter. Treat it as a delayed map of where the manager's conviction sat on the reporting date — not a live portfolio, and not a buy list.

Positions may have changed since the reporting date. Weight changes also reflect price moves, not only buying or selling — the action tags on this page are derived from share counts, which do not move with price.